Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | KLF10 | Q13118 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 4/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | SNCA | P37840 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30574768 | 1.00 | PTPN1 (0.37) | PTPN1ALOX15ALOX12KLF10KDM1A | |
| SCHEMBL24697715 | 0.86 | KDM1A (0.36) | PTPN1KDM1AKCNH2KDM1B | |
| SCHEMBL24133366 | 0.84 | ALOX15 (0.39) | PTPN1ALOX15ALOX12KLF10SNCA | |
| SCHEMBL856379 | 0.84 | KDM1A (0.39) | KDM1AKCNH2KDM1B | |
| SCHEMBL2034552 | 0.79 | PTPN1 (0.33) | PTPN1KDM1AKCNH2KDM1B | |
| SCHEMBL31028666 | 0.78 | KDM1A (0.36) | ALOX15KDM1AKCNH2KDM1B | |
| SCHEMBL23287049 | 0.78 | KDM1A (0.32) | PTPN1KDM1AKCNH2KDM1B | |
| SCHEMBL30296468 | 0.78 | KDM1A (0.44) | KDM1AKCNH2KDM1B | |
| SCHEMBL2554312 | 0.78 | KDM1A (0.44) | KDM1AKCNH2KDM1B | |
| SCHEMBL18784110 | 0.78 | KDM1A (0.46) | KDM1AKCNH2KDM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115600-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-04-10 | — | — | US | disclosed |
| EP-4486390-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | Terremoto Biosciences, Inc (US) | 2025-01-08 | — | — | EP | disclosed |
| WO-2023168291-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023168291-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-8492372-B2 | Modulators of dopamine neurotransmission | INTEGRATED RESEARCH LABORATORIES SWEDEN AB (SE) | 2013-07-23 | — | — | US | disclosed |
| EP-2271638-B1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB AF NEUROSEARCH SWEDEN AB (DK) | 2011-08-31 | — | — | EP | disclosed |
| US-20110112065-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2011-05-12 | — | — | US | disclosed |
| CN-102015674-A | Modulators of dopamine neurotransmission | NSAB AF NEUROSEARCH SWEDEN AB | 2011-04-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115600-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | AKT1, AKT1S1, AKT2 | PTPN1 1124/4885ALOX15 4309/4885ALOX12 4314/4885 |
| US-20110112065-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | SLC18A2, SYNGR2, DBH | PTPN1 2162/4885ALOX15 2102/4885ALOX12 2213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.